Caption Management’s Arcus Biosciences RCUS Stock Holding History

Caption Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$648K	Sell	30,000 -1,050,000	-97%	-$22.7M	﹤0.01%	1141
2025 Q4	$25.7M	Buy	+1,080,000	New	+$22M	0.18%	127
2024 Q4	–	Sell	-30,000	Closed	-$459K	–	1772
2024 Q3	$459K	Sell	30,000 -19,300	-39%	-$304K	0.01%	939
2024 Q2	$751K	Buy	+49,300	New	+$796K	0.01%	726
2024 Q1	–	Sell	-50,000	Closed	-$955K	–	1605
2023 Q4	$955K	Buy	+50,000	New	+$799K	0.01%	815
2023 Q3	–	Sell	-30,000	Closed	-$609K	–	1499
2023 Q2	$609K	Sell	30,000 -30,000	-50%	-$571K	0.01%	778
2023 Q1	$1.09M	Buy	60,000 +57,600	+2,400%	+$1.1M	0.02%	613
2022 Q4	$49.6K	Buy	+2,400	New	+$66K	﹤0.01%	1178
2022 Q3	–	Sell	-30,000	Closed	-$760K	–	1786
2022 Q2	$760K	Sell	30,000 -72,100	-71%	-$1.77M	0.01%	968
2022 Q1	$3.22M	Buy	+102,100	New	+$3.42M	0.04%	587
2020 Q3	–	Sell	-44,900	Closed	-$1.11M	–	1213
2020 Q2	$1.11M	Buy	+44,900	New	+$1.21M	0.04%	510

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Caption Management's RCUS Position: Q1 2026 in Review

Caption Management reduced its Arcus Biosciences (RCUS) stake by 98% in Q1 2026, selling an estimated $16.2M and leaving 16,033 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

Caption Management first reported a position in RCUS in Q1 2022 and has held it in 8 quarters since. The position peaked at $18.3M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

Caption Management held 16,033 shares of Arcus Biosciences worth $346K as of Q1 2026.
Caption Management sold 751,665 Arcus Biosciences shares in Q1 2026, an estimated $16.2M.
Arcus Biosciences made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1274 holding.
Caption Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 8 quarters since.
Caption Management's Arcus Biosciences position peaked at $18.3M in Q4 2025.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.